Financial Contrast: MaxCyte (MXCT) versus Its Competitors

MaxCyte (NASDAQ:MXCT) is one of 109 publicly-traded companies in the “Life Sciences Tools & Services” industry, but how does it compare to its competitors? We will compare MaxCyte to similar companies based on the strength of its dividends, institutional ownership, valuation, profitability, risk, analyst recommendations and earnings.

Volatility and Risk

MaxCyte has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500. Comparatively, MaxCyte’s competitors have a beta of 1.14, meaning that their average share price is 14% more volatile than the S&P 500.

Insider and Institutional Ownership

68.8% of MaxCyte shares are held by institutional investors. Comparatively, 54.4% of shares of all “Life Sciences Tools & Services” companies are held by institutional investors. 4.1% of MaxCyte shares are held by company insiders. Comparatively, 15.2% of shares of all “Life Sciences Tools & Services” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares MaxCyte and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MaxCyte	-114.77%	-18.92%	-16.14%
MaxCyte Competitors	-540.86%	-166.48%	-13.59%

Earnings & Valuation

This table compares MaxCyte and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
MaxCyte	$31.05 million	-$44.63 million	-5.24
MaxCyte Competitors	$2.29 billion	$55.11 billion	-0.34

MaxCyte’s competitors have higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of recent recommendations for MaxCyte and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	1	1	1	0	2.00
MaxCyte Competitors	943	3157	5466	175	2.50

MaxCyte presently has a consensus target price of $5.00, indicating a potential upside of 189.02%. As a group, “Life Sciences Tools & Services” companies have a potential downside of 8.27%. Given MaxCyte’s higher possible upside, equities research analysts clearly believe MaxCyte is more favorable than its competitors.

Summary

MaxCyte competitors beat MaxCyte on 8 of the 13 factors compared.

About MaxCyte

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.